Vizsgálati helyszín
Nizhny Novgorod
Nizhny Novgorod, 603081, OroszországMég nincs intézményhez kötve
- 20futó vizsgálat
- 13lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 34 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis11 vizsgálat
- 2. fázis4 vizsgálat
- Állapot
- Fut, nem toboroz16 vizsgálat
- Lezárult10 vizsgálat
- Toboroz4 vizsgálat
- Leállították3 vizsgálat
- Felfüggesztve1 vizsgálat
- Fő szponzor
- AstraZeneca31 vizsgálat
- Checkpoint Therapeutics, Inc.1 vizsgálat
- MedImmune LLC1 vizsgálat
- Otsuka Pharmaceutical Development & Commercialization, Inc.1 vizsgálat
Futó vizsgálatok
Fut, nem toboroz
A Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2
NCT07143604· 2. fázis· AstraZeneca· Forrás
Toboroz
Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration
NCT07052578· AstraZeneca· Forrás
Toboroz
TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation
NCT07038928· AstraZeneca· Forrás
Toboroz
Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsia
NCT07088991· AstraZeneca· Forrás
Fut, nem toboroz
A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)
NCT06606847· 2. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry Study
NCT06521229· AstraZeneca· Forrás
Toboroz
Clinical and demOgRaphic Features of Patients With Uncontrolled Severe Asthma in Russia (CORSAR)
NCT06472310· AstraZeneca· Forrás
Fut, nem toboroz
A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
NCT05941897· 2. fázis· AstraZeneca· Forrás
Fut, nem toboroz
CRT( Chemo-Radiation Therapy) Patterns and Short-term Outcomes on Unresectable NSCLC and SCLC in Routine Practices in Russia
NCT05887011· AstraZeneca· Forrás
Fut, nem toboroz
A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia
NCT05456867· AstraZeneca· Forrás
Fut, nem toboroz
CLL Therapy Approaches in Russia
NCT05140369· AstraZeneca· Forrás
Fut, nem toboroz
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
NCT04351555· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
NCT03800134· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
NCT03732677· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
NCT03682068· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
NCT03528694· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
NCT03298451· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Savolitinib vs. Sunitinib in MET-driven PRCC.
NCT03091192· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma
NCT01843374· 2. fázis· MedImmune LLC· Forrás
Fut, nem toboroz
Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.
NCT00099437· 3. fázis· AstraZeneca· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek